DNA Damage Repair Pathways in Prostate Cancer: A Narrative Review of Molecular Mechanisms, Emerging Biomarkers and Therapeutic Targets in Precision Oncology

被引:3
|
作者
Grypari, Ioanna-Maria [1 ]
Tzelepi, Vasiliki [2 ]
Gyftopoulos, Kostis [3 ]
机构
[1] Natl Kapodistrian Univ Athens, Aretaie Univ Hosp, Cytol Dept, Athens 11528, Greece
[2] Univ Patras, Sch Med, Dept Pathol, Patras 26504, Greece
[3] Univ Patras, Sch Med, Dept Anat, Patras 26504, Greece
关键词
prostate cancer; DNA damage repair; homologous recombination deficiency; mismatch repair pathway; biomarkers; MICROSATELLITE INSTABILITY; INTRADUCTAL CARCINOMA; PROMOTER HYPERMETHYLATION; RADICAL PROSTATECTOMY; PARP; INHIBITORS; THERAPIES; GERMLINE; RISK; PD-1;
D O I
10.3390/ijms241411418
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Prostate cancer (PCa) has a distinct molecular signature, including characteristic chromosomal translocations, gene deletions and defective DNA damage repair mechanisms. One crucial pathway involved is homologous recombination deficiency (HRD) and it is found in almost 20% of metastatic castrate-resistant PCa (mCRPC). Inherited/germline mutations are associated with a hereditary predisposition to early PCa development and aggressive behavior. BRCA2, ATM and CHECK2 are the most frequently HRD-mutated genes. BRCA2-mutated tumors have unfavorable clinical and pathological characteristics, such as intraductal carcinoma. PARP inhibitors, due to the induction of synthetic lethality, have been therapeutically approved for mCRPC with HRD alterations. Mutations are detected in metastatic tissue, while a liquid biopsy is utilized during follow-up, recognizing acquired resistance mechanisms. The mismatch repair (MMR) pathway is another DNA repair mechanism implicated in carcinogenesis, although only 5% of metastatic PCa is affected. It is associated with aggressive disease. PD-1 inhibitors have been used in MMR-deficient tumors; thus, the MMR status should be tested in all metastatic PCa cases. A surrogate marker of defective DNA repair mechanisms is the tumor mutational burden. PDL-1 expression and intratumoral lymphocytes have ambivalent predictive value. Few experimental molecules have been so far proposed as potential biomarkers. Future research may further elucidate the role of DNA damage pathways in PCa, revealing new therapeutic targets and predictive biomarkers.
引用
收藏
页数:26
相关论文
共 50 条
  • [1] Aberrations of DNA repair pathways in prostate cancer: a cornerstone of precision oncology
    Boussios, Stergios
    Rassy, Elie
    Shah, Sidrah
    Ioannidou, Evangelia
    Sheriff, Matin
    Pavlidis, Nicholas
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2021, 25 (05) : 329 - 333
  • [2] Genetic aberrations in DNA repair pathways: a cornerstone of precision oncology in prostate cancer
    Lozano, Rebeca
    Castro, Elena
    Aragon, Isabel M.
    Cendon, Ylenia
    Cattrini, Carlo
    Lopez-Casas, Pedro P.
    Olmos, David
    BRITISH JOURNAL OF CANCER, 2021, 124 (03) : 552 - 563
  • [3] Genetic aberrations in DNA repair pathways: a cornerstone of precision oncology in prostate cancer
    Rebeca Lozano
    Elena Castro
    Isabel M. Aragón
    Ylenia Cendón
    Carlo Cattrini
    Pedro P. López-Casas
    David Olmos
    British Journal of Cancer, 2021, 124 : 552 - 563
  • [4] Emerging molecular pathways and targets in neuroendocrine prostate cancer
    Monn, M. Francesca
    Montironi, Rodolfo
    Lopez-Beltran, Antonio
    Cheng, Liang
    TRANSLATIONAL CANCER RESEARCH, 2016, 5 : S282 - S285
  • [5] Emerging biomarkers and molecular targets for precision medicine in cervical cancer
    Garg, Pankaj
    Krishna, Madhu
    Subbalakshmi, Ayalur Raghu
    Ramisetty, Sravani
    Mohanty, Atish
    Kulkarni, Prakash
    Horne, David
    Salgia, Ravi
    Singhal, Sharad S.
    BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2024, 1879 (03):
  • [6] WIF1 and DKK3 in prostate cancer: from molecular pathways to therapeutic targets: a narrative review
    Xia, Zhiliang
    Du, Dan
    Zhang, Zhi
    Liu, Zonglai
    Hu, Zhonggui
    Li, Xinyu
    Guo, Xiong
    He, Ziqiu
    TRANSLATIONAL ANDROLOGY AND UROLOGY, 2024, 13 (11)
  • [7] A Narrative Review of Implementing Precision Oncology in Metastatic Castration-Resistant Prostate Cancer in Emerging Countries
    Bazarbashi, Shouki
    Su, Wen-Pin
    Wong, Siew W.
    Singarachari, Ramanujam A.
    Rawal, Sudhir
    Volkova, Maria I.
    Bastos, Diogo A.
    ONCOLOGY AND THERAPY, 2021, 9 (02) : 311 - 327
  • [8] A Narrative Review of Implementing Precision Oncology in Metastatic Castration-Resistant Prostate Cancer in Emerging Countries
    Shouki Bazarbashi
    Wen-Pin Su
    Siew W. Wong
    Ramanujam A. Singarachari
    Sudhir Rawal
    Maria I. Volkova
    Diogo A. Bastos
    Oncology and Therapy, 2021, 9 : 311 - 327
  • [9] Emerging therapeutic frontiers in prostate health: Novel molecular targets and classical pathways in comparison with BPH and prostate cancer
    Hassan, Muhammad Sajjad
    Irfan, Hafiz Muhammad
    Alamgeer
    Sarwar, Muavia
    Jabbar, Zeeshan
    Nawaz, Shoaib
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2025, 206
  • [10] Current and emerging tissue-based molecular biomarkers for prostate cancer management: A narrative review
    Jas Singh
    Uroprecision, 2023, 1 (03) : 128 - 139